Wegovy for PCOS weight loss: what the evidence actually supports

What did @laura_citlally actually say?

Honestly? Not much, medically speaking. The audio in this video is Billie Eilish's "everything i wanted," not a voiceover from the creator. The caption does the real talking: a year and a half on Wegovy, 60 injections, a PCOS diagnosis, and the line "this medication saved me." That's the claim we're fact-checking, because 348,000 people saw it.

The caption frames Wegovy as transformative for someone with PCOS, implies the journey was hard, and ends with "you are not alone." There's no dosing advice, no before-and-after weight claim, and no specific symptom list. What's here is personal testimony, which carries real weight with audiences even when no clinical detail is offered. We should take the emotional framing seriously without pretending it's a clinical statement.

Does the science back this up?

For PCOS and GLP-1 receptor agonists, the evidence is genuinely promising, though still maturing. A 2023 trial by Cena et al. published in the Journal of Clinical Endocrinology and Metabolism found that semaglutide (the active ingredient in Wegovy) improved menstrual regularity, reduced androgen levels, and drove meaningful weight loss in women with PCOS compared to placebo.

Earlier work by Elkind-Hirsch et al. (2022, Fertility and Sterility) using liraglutide, a related GLP-1 agonist, showed similar hormonal improvements. The mechanism makes sense: PCOS is tightly linked to insulin resistance, and GLP-1 agonists improve insulin sensitivity in addition to suppressing appetite. So the idea that Wegovy could be a meaningful intervention for PCOS is not wishful thinking. It's biologically coherent and increasingly supported by data. That said, semaglutide is not FDA-approved specifically for PCOS, and long-term data in this population is still limited.

What did they get wrong (or right)?

The creator got more right than wrong, given how little they actually claimed. Saying the medication "saved" them is personal language, not a medical declaration, and we shouldn't hold a patient's emotional experience to clinical trial standards. That's fair.

What's worth flagging is the implicit message that Wegovy is a straightforward solution for PCOS. The caption says it "has been difficult," which is honest. But 60 injections over 18 months represents a significant commitment, and the side effect profile of semaglutide, including nausea, vomiting, gastrointestinal distress, and potential muscle mass loss without resistance training, deserves more airtime than a trending audio clip allows. A 2022 review by Wilding et al. in Obesity Reviews noted that GI side effects affect up to 44 percent of users and are the primary reason for discontinuation. Someone watching this video might walk away thinking the hard part is emotional, not physical.

What should you actually know?

If you have PCOS and you're considering a GLP-1 agonist, the honest picture looks like this: the science is encouraging but not settled, the off-label use for PCOS is growing among endocrinologists, and results vary considerably depending on baseline insulin resistance, ovarian function, and lifestyle factors.

Wegovy requires a prescription and ongoing medical supervision. It is not interchangeable with compounded semaglutide products circulating online. Dosing is titrated over months, and stopping abruptly without a management plan often reverses weight loss gains, a point raised by Rubino et al. (2021, JAMA) in their withdrawal study. Women with PCOS who respond well to GLP-1 therapy often see improvements in cycle regularity and androgen symptoms, but these are secondary outcomes, not guaranteed effects. A reproductive endocrinologist or obesity medicine specialist is the right person to assess whether this fits your situation, not a TikTok comment section.

Bottom line

This video is sympathetic, honest about difficulty, and represents a real patient experience. It is not misinformation. It is also not medical guidance, and a quarter-million viewers should understand the difference. The case for GLP-1 agonists in PCOS is real. The case for treating one person's 18-month journey as a template for your own is not.

• PCOS affects 8 to 13 percent of reproductive-age women globally, according to the WHO, and insulin resistance is present in roughly 70 percent of cases.
• Semaglutide is approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic), not specifically for PCOS.
• Side effects are common and sometimes severe enough to require discontinuation. This is not a minor footnote.
• Wegovy and compounded semaglutide are not the same product and should not be treated as equivalent.